# Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

Source: https://onco.cc/trials/nct07217184/  
OnCo record `nct07217184` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belantamab mafodotin, Isatuximab in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM is a phase 1/2 interventional study registered as NCT07217184 by GlaxoSmithKline, with 30 participants enrolled, started 2021-07-29 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Isatuximab. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT07217184
- Phase: 1/2
- Setting: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination
- Sponsor: GlaxoSmithKline
- Enrolled: 30
- Outcomes: Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLT): 1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab 2 participants vs 1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab 0 participants vs 1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab 1 participants; DE Phase: Overall Response Rate (ORR): 1.9 Milligram (mg)/Kilogram (kg) Belantamab Mafodotin (Q4W) + Isatuximab 20% vs 1.4 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab 30% vs 1.9 mg/kg Belantamab Mafodotin (Q8W) + Isatuximab 30%

## Sources

- ClinicalTrials.gov NCT07217184: https://clinicaltrials.gov/study/NCT07217184

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Isatuximab](https://onco.cc/drugs/isatuximab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07217184.json